TrueTicker

NIFTY 500 › Healthcare

Healthcare · NIFTY 500

Vijaya Diagnostic Centre Ltd.

VIJAYA on NSE · 19 Nov 2026

NIFTY 500

1,510.60 ▼ -1.50 % on the day

Overview Technical Risk & rank Results Accounts Filings Guidance & governance

Filings

38 filings of VIJAYA since February 2025.

board outcome 14, presentation 9, transcript 8, scheme 3, results 2, dividend 2

FiledTypeSubject
06 Nov 2026transcript
Acquisition, Capex, Guidance, Results
Vijaya Diagnostic Centre Limited has informed the Exchange about Transcript
AI summary

Vijaya Diagnostic Centre filed the transcript of its Q2 FY27 earnings call held on November 04, 2026, after its unaudited results for the quarter and half year ended September 30, 2026.

Management reported Q2 consolidated revenue of about INR 255 crore, up 26.7% year-on-year, with EBITDA of about INR 113 crore (margin 44.1%) and PAT of INR 59 crore.

For H1 FY27, consolidated revenue was INR 486 crore (up 24.8%), EBITDA INR 211 crore (up 36%) and PAT INR 113 crore.

Management said it expects to commission 8 hub centres and 14 spoke centres by Q1 FY28 at estimated capex of INR 155-160 crore, and is acquiring Arya Wellness Centre, Guwahati, on a slump sale basis, expected to complete in about two months.

Management said at least 20% revenue growth is fairly achievable for FY27 and above 15% over three to five years.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Nov 2026presentation
Acquisition, Capex, Results
Vijaya Diagnostic Centre Limited has informed the Exchange about Investor Presentation
AI summary

Investor presentation for Q2 FY27 and H1 FY27 results (quarter and half year ended September 30, 2026), for an earnings call on November 4, 2026 at 11:00 A.M. IST.

Q2 FY27 revenue from operations INR 2,554 Mn, EBITDA INR 1,128 Mn (44.1% margin), PAT INR 595 Mn (23.3% margin); H1 FY27 revenue INR 4,864 Mn, EBITDA INR 2,113 Mn (43.4%), PAT INR 1,126 Mn (23.1%).

Management (Ms. Suprita Reddy, MD & CEO) said Q2 FY27 revenue grew 26.7% year-on-year on 16.5% volume growth, existing centres grew about 20%, and Pune showed consistent double-digit growth.

Management said 2 hubs and 7 spokes were commissioned so far in FY27, with 3 hubs and 7 spokes expected in H2 FY27 and 3 more hubs in Q1 FY28.

Management said the company entered a Business Transfer Agreement to acquire Arya Wellness Centre in Guwahati, Assam, its entry into the North-East region.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Nov 2026board outcome
Management change, Results
Vijaya Diagnostic Centre Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
AI summary

Board of Vijaya Diagnostic Centre Limited met on November 03, 2026 (meeting held 06:12 PM to 06:40 PM IST) and approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, with limited review reports from BSR and Co Chartered Accountants enclosed.

The Board appointed Mr. Rahul Jain as Company Secretary and Compliance Officer (Key Managerial Personnel) with effect from November 03, 2026.

Mr. Rahul Jain is a qualified Company Secretary and Associate Member of ICSI with over six years of experience in corporate secretarial functions and regulatory compliance.

The limited review report notes the amalgamation of Medinova Diagnostic Services Limited with the company, accounted for per the NCLT-approved scheme dated October 13, 2025, with prior periods restated.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
11 Sep 2026presentation
Acquisition, Capex
Vijaya Diagnostic Centre Limited has informed the Exchange about General Updates - Investor Presentation - 100% Acquisition of integrated diagnostic business undertaking of Arya Wellness Centre, Guwahati, Asssam.
AI summary

Vijaya Diagnostic Centre Limited filed an investor presentation on the acquisition, by slump sale under a Business Transfer Agreement (BTA), of the integrated diagnostic business of Arya Wellness Centre, Guwahati, Assam, from NEMRIL HRPL JV.

Transaction consideration is about ₹46 Cr for 100% of the business, funded from internal accruals, with adjusted FY26 IND AS EBITDA valuation of about 8-9x.

Arya Wellness Centre reported FY26 revenue from operations of INR 260 Mn, IND AS EBITDA of INR 56 Mn (21.4% margin) and adjusted PAT of INR 25 Mn (9.5% margin).

Indicative closing timeline is around Nov / Dec 2026, subject to conditions precedent.

Management (MD & CEO Suprita Reddy) said the acquisition is a natural extension of the company's West Bengal presence, gives a gateway to the North East, and is expected to be EPS accretive from the onset.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
11 Sep 2026board outcome
Acquisition
Vijaya Diagnostic Centre Limited has informed the Exchange regarding Outcome of Board Meeting held on September 11, 2026. (Approval for execution of Business Transfer Agreement ("BTA") for 100% acquisition of integrated diagnostic business
AI summary

Board of Vijaya Diagnostic Centre approved, on September 11, 2026, the acquisition of the integrated diagnostic business undertaking of Arya Wellness Centre on a slump sale basis from NEMRIL HRPL JV.

Lump-sum purchase consideration is ₹ 46.20 Crores in cash, subject to customary closing working capital adjustments, payable under the Business Transfer Agreement.

The target business had turnover of ₹ 26.95 Crores in FY 2025-26, ₹ 25.61 Crores in FY 2024-25 and ₹ 22.99 Crores in FY 2023-24, and operates in Guwahati, Assam.

Completion is subject to statutory and regulatory approvals and is tentatively expected within 90 days; the transaction is not a related party transaction.

The company said the acquisition expands its diagnostic business into Assam and strengthens its presence in North-East India.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
10 Aug 2026transcript
Capex, Guidance, Results
Vijaya Diagnostic Centre Limited has informed the Exchange about Transcript
AI summary

Vijaya Diagnostic Centre filed the transcript of its Q1 FY27 earnings conference call held on August 7, 2026, for the quarter ended June 30, 2026.

Management reported consolidated revenue of about Rs. 231 crores, up 22.8% year-on-year, with test volume growth of 16.5%; EBITDA of INR 98 crores (margin 42.7%, up 360 bps) and PAT of INR 53 crores, up 37.6%.

Management said it plans to commission 9 hub centres, 10 to 12 spoke centres and a Panjagutta reference laboratory, with capex of approximately INR 190-195 crores, and to acquire land in Andhra Pradesh for a hub at an estimated INR 8-10 crores.

Management stated the company has a surplus cash position of approximately INR 330 crores and expects cash PAT generation of about 26-27%.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Aug 2026presentation
Capex, Guidance, Results
Vijaya Diagnostic Centre Limited has informed the Exchange about Investor Presentation
AI summary

Vijaya Diagnostic Centre Limited filed its investor presentation on Q1 FY27 (quarter ended June 30, 2026) results, to be used in an earnings call on August 07, 2026 at 10:30 A.M. (IST).

Q1 FY27 revenue from operations was INR 2,310 Mn, up 22.8% year on year; EBITDA was INR 985 Mn (42.7% margin); PAT was INR 531 Mn (23.0% margin).

Q1 FY27 test volume was 4.59 Mn, up 16.5% year on year; footfall was 1.24 Mn; the company had 166 centres as at June 30, 2026.

Management (Ms. Suprita Reddy, MD & CEO) said a hub centre in Gachibowli, Hyderabad was commissioned in April 2026 and a flagship hub in JP Nagar, Bengaluru was commissioned in July 2026, and four spokes were added in the quarter.

Management plans to commission 9 hub centres and 10-12 spoke centres in the next 12 months.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Aug 2026board outcome
Dividend / buy-back, Results
Vijaya Diagnostic Centre Limited has informed the Exchange regarding Outcome of Board Meeting held on August 06, 2026.
AI summary

Vijaya Diagnostic Centre Limited's board on August 06, 2026 approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with a statutory auditor limited review report (unmodified).

Standalone revenue from operations for Q1 FY27 was Rs. 21,853.71 lakhs, up from Rs. 17,736.83 lakhs in the quarter ended June 30, 2025; profit for the period was Rs. 5,314.76 lakhs versus Rs. 3,905.02 lakhs a year earlier.

Standalone basic EPS for the quarter was Rs. 5.17 (not annualised), against Rs. 3.80 a year earlier.

The board had earlier, on May 07, 2026, recommended a dividend of Rs. 2 per equity share (200%) for FY 2025-26, subject to shareholder approval at the AGM.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Aug 2026board outcome
Results
Vijaya Diagnostic Centre Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
AI summary

Vijaya Diagnostic Centre Limited filed the outcome of its board meeting held on August 06, 2026, approving unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with limited review reports.

Standalone revenue from operations for the quarter ended June 30, 2026 was Rs. 21,853.71 lakhs, against Rs. 17,736.83 lakhs for the quarter ended June 30, 2025.

Standalone profit for the period was Rs. 5,314.76 lakhs for the quarter ended June 30, 2026, against Rs. 3,905.02 lakhs a year earlier.

Standalone basic EPS was Rs. 5.17 for the quarter ended June 30, 2026 (not annualised), against Rs. 3.80 a year earlier.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
09 Jul 2026board outcome
Management change
Vijaya Diagnostic Centre Limited has informed the Exchange regarding Outcome of Board Meeting held on July 09, 2026.
AI summary

Board of Vijaya Diagnostic Centre Limited approved the appointment of Mr. Narasimha Raju K.A. as Chief Financial Officer, effective July 09, 2026.

Mr. Narasimha Raju is a Chartered Accountant with over 20 years of experience; he was previously CFO of the Company from March 15, 2021 to March 26, 2025 and most recently CFO of Yashoda Group of Hospitals.

The Board meeting was held on July 09, 2026, from 17:30 hrs to 17:40 hrs.

No disclosure of relationships between directors was made, as the appointment is not of a director.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 May 2026transcript
Capex, Guidance, Results
Vijaya Diagnostic Centre Limited has informed the Exchange about Transcript
AI summary

Transcript of Vijaya Diagnostic Centre's Q4 FY26 earnings call held on May 8, 2026, filed May 13, 2026.

Management reported Q4 FY26 consolidated revenue of INR 219 crores, up 26.6% Y-o-Y, with test volume growth of 18.5%; EBITDA of INR 95.5 crores (43.5% margin) and PAT of INR 47.9 crores.

For FY26, consolidated revenue was INR 814 crores (up 19.5%), EBITDA INR 337 crores (41.4% margin) and PAT INR 173 crores; overall capex was INR 169 crores.

Management estimated FY27 capital outlay for new centres, including the automated lab, at INR 140-150 crores, and said it expects EBITDA margin of 30%+ while opening new centres, with 40% as a conservative margin guidance.

Management plans to commission 4-5 hubs and 10-12 spokes in FY27 and described Genomics as a long-term play with no significant revenue expected in the next few years.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
07 May 2026presentation
Capex, Guidance, Results
Vijaya Diagnostic Centre Limited has informed the Exchange about Investor Presentation
AI summary

Vijaya Diagnostic Centre Limited filed its investor presentation on Q4 and FY26 financial results (quarter and year ended March 31, 2026), to be used in an earnings call on May 08, 2026 at 2:00 PM IST.

Q4 FY26: revenue from operations INR 2,194 Mn, EBITDA INR 955 Mn (43.5% margin), PAT INR 479 Mn (21.8% margin).

FY26: revenue from operations INR 8,142 Mn, EBITDA INR 3,369 Mn (41.4% margin), PAT INR 1,730 Mn (21.2% margin).

Management (MD & CEO Suprita Reddy) said FY26 revenue crossed INR 800 Cr with a 16.5% CAGR over five years since listing, and Q4 FY26 was the highest-ever quarterly revenue at INR 219 Cr, up about 26.5% YoY.

Management plans 4-5 hubs and 10-12 spokes in FY27, a fully automated laboratory at Panjagutta, Hyderabad, and advanced genomic testing.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
07 May 2026board outcome
Acquisition, Dividend / buy-back, Management change, Results
Vijaya Diagnostic Centre Limited has informed the Exchange regarding Outcome of Board Meeting held on May 07, 2026.
AI summary

Board outcome for quarter and year ended March 31, 2026: audited standalone and consolidated financial results approved.

Final dividend of ₹2 per equity share (200% on face value of ₹1) recommended for FY2025-26, subject to shareholder approval at the AGM; AGM and record dates to be announced later.

Dr. D Nageshwar Reddy (DIN: 00324725) will not seek re-appointment for a second five-year term as Independent Director; his current term ends May 25, 2026 (close of business), citing pre-occupation and other professional commitments.

Board approved re-appointment of Santhosh & Associates as Cost Auditors for FY2026-27.

Grant of 1,79,500 ESOPs under the VDCL Employee Stock Option Plan 2018, convertible into 1,79,500 equity shares of ₹1 each; board also approved acquisition of MRI, EEG and NCV services business from Medinova Millennium MRI Services LLP, a wholly owned subsidiary.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
07 May 2026dividend
Acquisition, Dividend / buy-back, Management change, Results
Vijaya Diagnostic Centre Limited has informed the Exchange that Board of Directors at its meeting held on May 07, 2026, recommended Final Dividend of Rs. 2 per equity share.
AI summary

Board meeting outcome dated May 07, 2026: audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 considered and approved.

Board recommended a final dividend of ₹2 per equity share (200% on face value of ₹1), subject to shareholder approval at the forthcoming AGM; AGM and record date to be announced later.

Dr. D Nageshwar Reddy (DIN: 00324725) will not seek re-appointment for a second five-year term as Independent Director; his current term ends May 25, 2026 (close of business), citing pre-occupation and professional commitments.

Board also approved re-appointment of Santhosh & Associates as Cost Auditors for FY 2026-27, grant of 1,79,500 ESOPs under the VDCL Employee Stock Option Plan 2018, and acquisition of MRI, EEG and NCV services business from wholly owned subsidiary Medinova Millennium MRI Services LLP.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
07 May 2026board outcome
Dividend / buy-back, Results
Vijaya Diagnostic Centre Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AI summary

Board of Vijaya Diagnostic Centre Limited approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 on May 07, 2026, with unmodified audit opinions.

Standalone revenue from operations for Q4 FY26 was Rs. 20,626.71 lakhs and for FY26 was Rs. 76,542.88 lakhs, versus Rs. 16,163.85 lakhs in Q4 FY25 and Rs. 63,400.30 lakhs in FY25.

Standalone profit for the period for Q4 FY26 was Rs. 5,265.14 lakhs and for FY26 was Rs. 17,831.03 lakhs, versus Rs. 3,342.48 lakhs in Q4 FY25 and Rs. 13,592.97 lakhs in FY25.

The Board recommended a dividend of Re. 2 per equity share of Re. 1 each (200%) for FY 2025-26, subject to shareholder approval at the AGM.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
19 Feb 2026transcript
Capex, Guidance, Management change, Results
Vijaya Diagnostic Centre Limited has informed the Exchange about Transcript
AI summary

Vijaya Diagnostic Centre filed the transcript of its Q3 FY26 earnings conference call held on February 13, 2026, after results for the quarter and nine months ended December 31, 2025.

Management said consolidated revenue for Q3 FY26 was about INR 205 crores, up 21.4% year-on-year, with EBITDA of about INR 86 crores (41.9% margin) and PAT of about INR 43 crores.

For the nine months, management reported consolidated revenue of about INR 595 crores (up 17.1%), EBITDA of INR 241 crores and PAT of INR 125 crores.

Management said capex of INR 159 crores had been incurred till date in FY26, and estimated FY27 new-centre capex at INR 100 crores to INR 120 crores.

Management also announced new CFO Ankit Shah and the appointment of a new Chief Technology Officer and Lab Director, and said it expects 4-5 hubs and 10-12 spokes in FY27.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Feb 2026presentation
Acquisition, Management change, Results
Vijaya Diagnostic Centre Limited has informed the Exchange about Investor Presentation
AI summary

Vijaya Diagnostic Centre filed its investor presentation on Q3 and 9M FY26 results (quarter and nine months ended December 31, 2025), for the earnings call on February 13, 2026 at 5:00 PM IST.

Q3 FY26: revenue from operations INR 2,052 Mn, EBITDA INR 861 Mn (41.9% margin), PAT INR 432 Mn (21.0% margin); revenue growth 21.4%, test volume growth 14.7%.

9M FY26: revenue from operations INR 5,948 Mn, EBITDA INR 2,414 Mn (40.6% margin), PAT INR 1,251 Mn (21.0% margin).

Management (Ms. Suprita Reddy, MD & CEO) said revenues in Q3 surpassed Q2 in absolute terms, two West Bengal hubs launched in Q1 FY26 reached break-even within three quarters, and a CFO, CTO and COO were added to the leadership team.

Medinova Diagnostic Services Limited, Kolkata was merged with the company effective April 1, 2024 under an NCLT Hyderabad order dated October 13, 2025, and prior-period numbers were restated.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Feb 2026board outcome
Results
Vijaya Diagnostic Centre Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
AI summary

Board of Vijaya Diagnostic Centre Limited approved unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025 at a meeting held 13 February 2026 (12:30 PM to 2:30 PM IST).

Standalone Q3 FY26 revenue from operations was Rs. 19,308.31 lakhs and profit for the period was Rs. 4,421.24 lakhs, against Rs. 15,770.93 lakhs and Rs. 3,372.96 lakhs in the quarter ended 31 December 2024.

Standalone nine-month revenue from operations was Rs. 55,916.17 lakhs and profit for the period was Rs. 12,565.89 lakhs, against Rs. 47,236.45 lakhs and Rs. 10,250.48 lakhs in the nine months ended 31 December 2024.

Basic EPS for the nine months ended 31 December 2025 was Rs. 12.22 (not annualised), against Rs. 9.98 a year earlier.

The results follow the amalgamation of subsidiary Medinova Diagnostic Services Limited, sanctioned by NCLT on 13 October 2025 and accounted for under the pooling of interest method, with comparatives restated; the statutory auditor issued an unmodified limited review report.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Feb 2026board outcome
Dividend / buy-back, Legal, Management change, Results
Vijaya Diagnostic Centre Limited has informed the Exchange regarding Board meeting held on February 13, 2026.
AI summary

Board of Vijaya Diagnostic Centre Limited met on February 13, 2026 and approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (figures not shown in the pages provided).

Board appointed Mr. Ravi Shankararamiah and Dr. Sasikala Paruchuri Kola as additional Non-Executive Independent Directors for 5 years from February 13, 2026, subject to shareholder approval.

Noted the resignation of Mr. S. Ramachandra Reddy as Chief Financial Officer, effective February 13, 2026.

Appointed Mr. Ankit Shah as CFO, Mr. Sai Prasad as Chief Technology Officer and Mr. Venkata Siva Rama Raju Vegesna as Chief Operating Officer, all effective February 13, 2026.

Granted 1,15,000 Employee Stock Options under the VDCL Employee Stock Option Plan 2018, convertible into 1,15,000 equity shares of face value ₹1 each, and revised the Related Party Transaction Policy.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
07 Nov 2025transcript
Acquisition, Capex, Guidance, Results
Vijaya Diagnostic Centre Limited has informed the Exchange about Transcript
AI summary

Vijaya Diagnostic Centre filed the transcript of its Q2 FY26 earnings conference call held November 04, 2025, following its unaudited results for the quarter and half year ended September 30, 2025.

Management (MD & CEO Suprita Reddy) said consolidated revenue for Q2 was Rs.202 crores, up 10.2% year-on-year and 7.2% quarter-on-quarter, with EBITDA margin of 40.6% and PAT margin of 21.5%; half-year revenue was INR390 crores (around 15% year-on-year growth), EBITDA INR155 crores (40% margin) and PAT around INR82 crores (21% margin).

Management said the NCLT approved the merger with Medinova Diagnostic Services Limited in October, effective April 1, 2024, and that Yelahanka hub in Bengaluru reached break-even within two quarters.

Management attributed the slower Q2 growth to lower monsoon-related disease incidence, the early festive season, and a higher base, and said early Q3 footfalls had increased.

Management said surplus cash was around Rs.235 crores as at September 30, 2025 (actual cash around Rs.295 crores), excluding deferred capital creditors.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
04 Nov 2025presentation
Acquisition, Capex, Legal, Results
Vijaya Diagnostic Centre Limited has informed the Exchange about Investor Presentation
AI summary

Vijaya Diagnostic Centre filed its investor presentation for Q2 and H1 FY26 results (quarter and half year ended September 30, 2025), for an earnings call on November 04, 2025 at 5:00 PM IST.

Q2 FY26: revenue from operations INR 2,016 Mn (10.2% YoY growth), EBITDA INR 818 Mn (40.6% margin), PAT INR 433 Mn (21.5% margin).

H1 FY26: revenue from operations INR 3,896 Mn (14.9% YoY growth), EBITDA INR 1,554 Mn (39.9% margin), PAT INR 819 Mn (21.0% margin).

Management (Ms. Suprita Reddy, MD & CEO) said growth was largely volume-driven and reported the Kasba hub centre in Kolkata launched in the quarter, with two more West Bengal hubs expected in Q3 FY26.

Management said the Yelahanka hub in Bengaluru reached break-even within two quarters, ahead of the projected one year, and that the lease for a Bannerghatta, Bengaluru flagship centre has been finalised.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
04 Nov 2025board outcome
Acquisition, Capex, Legal, Results
Vijaya Diagnostic Centre Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
AI summary

Board of Vijaya Diagnostic Centre Limited (Nov 4, 2025) approved unaudited standalone and consolidated results for Q2 and half year ended September 30, 2025, with limited review reports enclosed.

NCLT Hyderabad order dated October 13, 2025 sanctioning the amalgamation of Medinova Diagnostic Services Limited into the company became effective on November 4, 2025; Medinova stands dissolved without winding up.

Share exchange ratio: 1 equity share of INR 1 each of the company for every 22 equity shares of INR 10 each held in Medinova; appointed date April 1, 2024; record date November 25, 2025.

The company's 62,02,220 shares (62.14%) in Medinova held by it are cancelled; authorised share capital raised to INR 230,500,000.

Medinova Millennium MRI Services LLP becomes a wholly owned subsidiary of the company from November 4, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
04 Nov 2025board outcome
Acquisition, Dividend / buy-back, Legal, Management change, Results
Vijaya Diagnostic Centre Limited has informed the Exchange regarding Board meeting held on November 04, 2025.
AI summary

Board outcome for quarter and half year ended September 30, 2025: unaudited standalone and consolidated financial results with limited review reports enclosed.

NCLT Hyderabad order dated October 13, 2025 sanctioning amalgamation of Medinova Diagnostic Services Limited into Vijaya Diagnostic Centre Limited; scheme effective November 04, 2025, appointed date April 01, 2024.

Share exchange ratio: 22 equity shares of INR 10 each of Medinova make 1 equity share of INR 1 each of Vijaya; record date November 25, 2025.

Medinova dissolved without winding up; 62,02,220 shares (62.14% stake) held by Vijaya in Medinova cancelled; authorised share capital increased to INR 230,500,000.

Medinova Millennium MRI Services LLP becomes a wholly owned subsidiary of Vijaya Diagnostic Centre Limited from November 04, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
18 Oct 2025scheme
Acquisition, Legal
Vijaya Diagnostic Centre Limited has informed the Exchange about Amalgamation/Merger
AI summary

Vijaya Diagnostic Centre Limited received the certified true copy of the final order dated October 13, 2025 from the NCLT, Hyderabad, approving the Scheme of Amalgamation between Medinova Diagnostic Services Limited (Transferor Company) and Vijaya Diagnostic Centre Limited (Transferee Company).

The Effective Date will be the date the NCLT order and certified Scheme are filed with the jurisdictional Registrar of Companies, Hyderabad; the company will inform exchanges when the sanction order is filed and the Scheme becomes effective.

The record date for determining eligible public shareholders of Medinova Diagnostic Services Limited for allotment of Vijaya Diagnostic Centre Limited equity shares will be informed in due course.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
16 Oct 2025scheme
Acquisition, Legal
Vijaya Diagnostic Centre Limited has informed the Exchange about Amalgamation/Merger
AI summary

Intimation under Regulation 30 of SEBI Listing Regulations that NCLT Hyderabad Bench pronounced its final order on October 13, 2025 sanctioning the Scheme of Amalgamation of Medinova Diagnostic Services Limited (Transferor Company) into Vijaya Diagnostic Centre Limited (Transferee Company).

The order was uploaded to the NCLT website on October 16, 2025, and a copy is enclosed.

The Appointed Date of the Scheme is April 01, 2024.

The company is obtaining the certified true copy of the order and will notify the exchanges on receipt; the Effective Date will be communicated once the order and scheme are filed with the Registrar of Companies, Hyderabad.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
29 Sep 2025scheme
Acquisition, Legal
Vijaya Diagnostic Centre Limited has informed the Exchange about Scheme of Arrangement
AI summary

Vijaya Diagnostic Centre Limited filed an update on the Scheme of Amalgamation of Medinova Diagnostic Services Limited (Transferor Company) with Vijaya Diagnostic Centre Limited (Transferee Company).

The NCLT Hyderabad Bench heard the matter on September 26, 2025 and reserved its order on the scheme.

The scheme is on a going concern basis with an appointed date of April 01, 2024.

The website-uploaded and certified copies of the order are awaited and will be submitted to the exchanges on receipt.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
02 Aug 2025transcript
Capex, Guidance, Results
Vijaya Diagnostic Centre Limited has informed the Exchange about Transcript
AI summary

Vijaya Diagnostic Centre filed the transcript of its Q1 FY'26 earnings conference call held on July 28, 2025, for the quarter ended June 30, 2025.

Management (Sunil Reddy) said consolidated revenue was Rs.188 crores, up about 20.4% year-on-year, driven by 17% test volume growth and change in test mix; patient footfall grew 14%.

Management said EBITDA margin was 39.1% and PAT margin 20.4%, despite the drag from launching multiple hubs; five hubs and one spoke were commissioned in the quarter, with 10 hubs planned for FY'26.

Management said the cash position as on June 30 was about Rs. 270 crores, or about Rs. 220 crores net of capital creditors.

For FY'26, Dhiren Gala guided overall capex for newer centers of around Rs. 150-155 crores and replacement capex of 2%-3% of topline; management said it is not participating in government PPP models, by choice, to focus on B2C.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
28 Jul 2025presentation
Capex, Results
Vijaya Diagnostic Centre Limited has informed the Exchange about Investor Presentation
AI summary

Vijaya Diagnostic Centre filed its Q1 FY26 investor presentation (quarter ended June 30, 2025) for the earnings call held July 28, 2025 at 5:00 PM IST.

Q1 FY26 revenue from operations was INR 1,881 Mn, up 20.4% year on year; EBITDA was INR 735 Mn at a 39.1% margin; PAT was INR 383 Mn at a 20.4% margin.

Tests performed were 3.94 Mn and footfall 1.10 Mn; the company had 157 centres as at June 30, 2025.

Management (MD & CEO Suprita Reddy) said the Hyderabad market returned to double-digit growth, and the new hubs in Pune, Bengaluru and West Bengal are operating with steady footfall.

Management said the Nizamabad hub reached break-even within two quarters of full operations, and three hubs are to be commissioned in Q2 FY26.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
28 Jul 2025board outcome
Dividend / buy-back, Management change, Results
Vijaya Diagnostic Centre Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
AI summary

Vijaya Diagnostic Centre Limited's board met on July 28, 2025 and approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, along with limited review reports.

The board granted 2,500 Employee Stock Options under the VDCL Employee Stock Option Plan 2018, convertible into 2,500 equity shares of face value ₹1 each, at an exercise price of ₹780 per option.

The board appointed M/s. Balaramakrishna & Associates, Practicing Company Secretaries, as Secretarial Auditor for five consecutive financial years, FY 2025-26 to FY 2029-30.

The board meeting commenced at 12:00 hrs and concluded at 13:15 hrs.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
28 Jul 2025board outcome
Dividend / buy-back, Results
Vijaya Diagnostic Centre Limited has informed the Exchange regarding Board meeting held on July 28, 2025.
AI summary

Vijaya Diagnostic Centre Limited filed the outcome of its board meeting held on July 28, 2025.

The board approved unaudited standalone and consolidated financial results for the first quarter ended June 30, 2025, with limited review reports enclosed.

The board granted 2,500 Employee Stock Options under the VDCL Employee Stock Option Plan 2018, convertible into 2,500 equity shares of ₹1 face value each, at an exercise price of ₹780 per option.

The board appointed M/s. Balaramakrishna & Associates as Secretarial Auditor for five consecutive financial years, FY 2025-26 to FY 2029-30.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
15 May 2025transcript
Capex, Guidance, Results
Vijaya Diagnostic Centre Limited has informed the Exchange about Transcript
AI summary

Vijaya Diagnostic Centre filed the transcript of its Q4 FY25 earnings conference call held on May 12, 2025, following audited results for the quarter and year ended March 31, 2025.

Management said consolidated revenue for Q4 was INR173 crores (up 12%, 13% organic) with EBITDA of INR69 crores (39.8% margin) and PAT of INR35 crores; full-year revenue was INR681 crores (up 24%, 19% organic), EBITDA INR273 crores (40.1% margin) and PAT INR143 crores.

Management said six new hubs were launched in the last two months (Pune, Bengaluru, West Bengal), with three more in West Bengal due in 3 to 4 months and two Tier 2 hubs in AP and Telangana due in H2 FY26.

Management guided to FY26 capex of roughly INR145 crores to INR150 crores and an EBITDA margin dip of 1% to 2% until new hubs break even, with margins expected back to regular levels by end FY26.

Management expects about 15% to 16% revenue CAGR over the next few years, with 1% to 2% from value and the rest from volume, and said wellness (about 15% of revenue) is weighing on gross margin.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 May 2025presentation
Capex, Results
Vijaya Diagnostic Centre Limited has informed the Exchange about Investor Presentation
AI summary

Vijaya Diagnostic Centre Limited filed its investor presentation on Q4 and FY25 financial results, for use in an earnings call on May 12, 2025 at 1800 hrs IST.

Q4 FY25 revenue from operations was INR 1,732 Mn (INR 1,621 Mn excluding PH); Q4 EBITDA INR 689 Mn (39.8% margin); Q4 PAT INR 346 Mn (20.0% margin).

FY25 revenue from operations was INR 6,814 Mn (INR 6,356 Mn excluding PH); FY25 EBITDA INR 2,732 Mn (40.1% margin); FY25 PAT INR 1,431 Mn (21.0% margin).

FY25 revenue growth was 24.4% year on year, with organic growth of 18.9% excluding PH, as stated by MD & CEO Suprita Reddy.

Management said it launched 6 hubs in the last two months (2 each in Pune, West Bengal and Bengaluru), with 3 more hubs in West Bengal expected to be commercialised in 3 to 4 months and two Tier-2 hubs in AP and Telangana due to become operational in H2 FY26.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 May 2025dividend
Dividend / buy-back, Management change, Results
Vijaya Diagnostic Centre Limited has informed the Exchange that Board of Directors at its meeting held on May 12, 2025, recommended Final Dividend of 2 per equity share.
AI summary

Board of Vijaya Diagnostic Centre Limited approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, with unmodified audit opinions from statutory auditors.

Board recommended a final dividend of ₹2 per equity share (200% on face value of ₹1), subject to shareholder approval at the forthcoming AGM; AGM and record dates to be announced later.

S. Ramachandra Reddy appointed Interim Chief Financial Officer and Key Managerial Personnel w.e.f. May 12, 2025.

Lanka Sai Srinivas appointed Chief Technology Officer w.e.f. May 12, 2025, as part of senior management.

M/s. Santhosh & Associates re-appointed as Cost Auditors for FY 2025-26.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 May 2025board outcome
Dividend / buy-back, Management change, Results
Vijaya Diagnostic Centre Limited has informed the Exchange regarding Audited Financial Results for the quarter and year ended March 31, 2025.
AI summary

Board of Vijaya Diagnostic Centre Limited, meeting held May 12, 2025, approved audited standalone and consolidated results for the quarter and year ended March 31, 2025, with unmodified audit opinions.

The Board recommended a final dividend of ₹2 per equity share (200% on face value of ₹1) for FY2025, subject to shareholder approval at the AGM; AGM and record dates to be announced later.

The Board appointed S. Ramachandra Reddy as Interim Chief Financial Officer and Key Managerial Personnel, and Lanka Sai Srinivas as Chief Technology Officer, both effective May 12, 2025.

The Board re-appointed Santhosh & Associates as Cost Auditors for FY2025-26.

The Nomination and Remuneration Committee granted 1,91,150 ESOPs under the VDCL Employee Stock Option Plan 2018.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
17 Feb 2025transcript
Capex, Guidance, Results
Vijaya Diagnostic Centre Limited has informed the Exchange about Earnings Call Transcript.
AI summary

Vijaya Diagnostic Centre filed the transcript of its Q3 FY25 earnings conference call held on February 12, 2025, covering results for the quarter and nine months ended December 31, 2024.

Management said consolidated revenue for the quarter was INR 169 crores, up 27% year-on-year, with 20% organic growth excluding PH Pune; EBITDA was INR 67 crores with a 39.7% margin, and PAT was INR 35 crores.

For the nine months, management reported consolidated revenue of INR 508 crores (up 29%), EBITDA of INR 204 crores and PAT of INR 108 crores.

Management said it plans to commission 9 more hub centres over the next 6 months and expects a slight near-term impact on EBITDA margins, which it expects to normalise as the new hubs ramp up.

Management guided to around 15% year-on-year growth, with about 13% from volume, and said capex for 12 hub centres is budgeted at INR 200 crores.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 Feb 2025results
Acquisition, Legal, Results
Integrated Filing - Financials for the quarter and nine months ended December 31, 2024
AI summary

Vijaya Diagnostic Centre Limited filed its unaudited standalone results for the quarter and nine months ended December 31, 2024, with the limited review report from BSR and Co.

Q3 FY25 revenue from operations was Rs. 15,625.54 lakhs and profit for the period was Rs. 3,353.25 lakhs, against Rs. 12,911.78 lakhs revenue and Rs. 2,524.64 lakhs profit in the year-ago quarter.

For the nine months to December 31, 2024, revenue from operations was Rs. 46,728.51 lakhs and profit was Rs. 10,189.36 lakhs, with basic EPS of Rs. 9.93.

The Board approved a proposed scheme of amalgamation under which subsidiary Medinova Diagnostic Services Limited would merge into the company with effect from April 1, 2024; SEBI, BSE and NSE gave "no adverse observations" on December 5, 2024, and the scheme remains subject to shareholder, creditor and NCLT approvals.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 Feb 2025presentation
Capex, Management change, Results
Vijaya Diagnostic Centre Limited has informed the Exchange about Investor Presentation
AI summary

Vijaya Diagnostic Centre filed its Q3 & 9M FY25 earnings investor presentation (quarter and nine months ended December 31, 2024), for an earnings call on February 12, 2025 at 05:30 p.m. IST.

Q3 FY25 revenue from operations was INR 1,690 Mn (INR 1,580 Mn excluding PH), with EBITDA of INR 671 Mn (39.7% margin) and PAT of INR 352 Mn (20.8% margin).

9M FY25 revenue from operations was INR 5,081 Mn (INR 4,736 Mn excluding PH), with EBITDA of INR 2,044 Mn (40.2% margin) and PAT of INR 1,084 Mn (21.3% margin).

Management (MD & CEO Ms. Suprita Reddy) said Q3 revenue grew 27.3% year on year, or 20.2% organically, driven mainly by volume in Pathology and Radiology.

Management said 6 hubs are to be commissioned across Pune, West Bengal and Bengaluru in the coming 3 months, taking hub additions to 9 in 12 months, and that the first PH-brand centre at Pimple Saudagar, Pune was operationalized in the month.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 Feb 2025results
Acquisition, Legal, Results
Vijaya Diagnostic Centre Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
AI summary

Vijaya Diagnostic Centre Limited filed its unaudited standalone financial results for the quarter and nine months ended December 31, 2024, approved by the Board on February 12, 2025.

Q3 FY25 (quarter ended Dec 31, 2024): revenue from operations Rs. 15,625.54 lakhs, profit after tax Rs. 3,353.25 lakhs, basic EPS Rs. 3.26.

Nine months ended Dec 31, 2024: revenue from operations Rs. 46,728.51 lakhs (vs Rs. 38,397.07 lakhs a year earlier), profit after tax Rs. 10,189.36 lakhs (vs Rs. 8,409.29 lakhs), basic EPS Rs. 9.93.

The filing notes a Scheme of Amalgamation under which subsidiary Medinova Diagnostic Services Limited would merge into the company with effect from April 1, 2024; BSE, NSE and SEBI issued "no adverse observations" on December 5, 2024, and the scheme remains subject to shareholder, creditor and NCLT approvals.

Statutory auditors BSR and Co issued a limited review report with an unmodified conclusion; the filing also includes the consolidated results and their limited review report.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy

The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in